{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-24-000051","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.378330+00:00","generated_at":"2026-05-30T03:25:33.486952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vistagen Q2 FY2025 net loss $13.0M; Phase 3 SAD trials on track for 2025 data","bullets":["Net loss of $13.0M for Q2 ended Sep 30, 2024 vs $6.6M a year ago, driven by higher R&D costs.","R&D expense $10.2M (up from $3.9M) due to fasedienol PALISADE Phase 3 program costs.","Cash, cash equivalents and marketable securities $97.6M as of Sep 30, 2024.","PALISADE-3 and PALISADE-4 Phase 3 trials for fasedienol in social anxiety disorder actively recruiting; top-line results expected in 2025.","Itruvone Phase 2B prep for MDD and PH80 IND-enabling program for menopausal hot flashes ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-24-000051","json":"https://secwatch.observer/filing/0001411685-24-000051.json","markdown":"https://secwatch.observer/filing/0001411685-24-000051.md","text":"https://secwatch.observer/filing/0001411685-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000051/0001411685-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168524000051/vtgn-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:25:33.486952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}